Abstract:Post-translational modifications of proteins such as protein ubiquitination are crucial for regulating conformation, stability and localization of the modified protein. Ubiquitin-specific protease 2 (USP2), a multifunctional cysteine protease is reported to be a key regulator of ubiquitylation events in numerous oncogenic proteins e.g., fatty acid synthetase, Mdm2, EGFR, cyclin A1, and cyclin-D1, etc. Thus targeting USP2 is a promising strategy for cancer therapy. USP2 is characterized by a catalytic triad comprising of cysteine, histidine and aspartic acid residues. Five residues including three from the catalytic triad and two from outside of the catalytic triad have been reported as a catalytic site of USP2 that catalyze hydrolysis and stabilizes the oxyanion formed in the intermediate step of catalysis. Here, we report two more novel residues (L269 and Y558) on USP2 involved in the catalysis of Ubiquitin using computational alanine scanning (CAS) followed by molecular dynamic simulation studies. The results obtained from CAS were further validated by a highly reliable, time- and cost-effective SDS-PAGE-based kinetics assay using UBA52 which is a natural substrate of USP2. Our results showed that mutating L269 and Y558 significantly compromised the catalytic efficiency of USP2 in hydrolyzing UBA52 which can further be extended to rational drug design of USP2 selective inhibitors and to explore the catalytic sites of other USPs. Two novel residues take part in catalytic activity of USP2 which were depicted by MD Simulations and were further validated by novel SDS-PAGE-based reliable time- and cost-effective kinetics assay.

Discovery of Novel USP8 Inhibitors Via Ubiquitin-Rho-110 Fluorometric Assay Based High Throughput Screening.

Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer Through Regulating ERα Expression

Discovery of Ubiquitin-Specific Protease 7 (USP7) Inhibitors with Novel Scaffold Structures by Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade

In silico screening and computational evaluation of novel promising USP14 inhibitors targeting the palm-thumb pocket

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

Development of a robust HTRF assay with USP7 full length protein expressed in E. coli prokaryotic system for the identification of USP7 inhibitors

Structure-based Virtual Screening of Novel USP5 Inhibitors Targeting the Zinc Finger Ubiquitin-Binding Domain

An Ultrasensitive System for Measuring the USPs and OTULIN Activity Using Nanoluc As a Reporter.

Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo Activity

Virtual Screening Inhibitors of Ubiquitin‐specific Protease 7 combining Pharmacophore Modeling and Molecular Docking

Gardenin B, a Natural Inhibitor for USP7: in Vitro Evaluation and in Silico Identification

Synthesis and structure–activity relationships of USP48 deubiquitinylase inhibitors

Development of a highly reliable assay for ubiquitin-specific protease 2 inhibitors.

Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer

Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers

Validation of Catalytic Site Residues of Ubiquitin Specific Protease 2 (USP2) by Molecular Dynamic Simulation and Novel Kinetics Assay for Rational Drug Design

The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364

Structure-based discovery of potent USP28 inhibitors derived from Vismodegib

Virtual screening of natural products targeting ubiquitin-specific protease 7

Discovery of potent and selective activity-based probes (ABPs) for the deubiquitinating enzyme USP30